In this serious condition, your retina -- a thin layer of nerve tissue in the back of your eye-- pulls away from its normal spot. There are three different types of retinal detachment ...

A new retinal stimulation technique called Oz enabled volunteers to see colours that lie beyond the natural range of human vision. Developed by researchers at UC Berkeley, Oz works by stimulating ...

A detached retina occurs when the retina, a layer of tissue that covers most of the back of the eye, separates from its anchored position. Eye trauma is the most common cause, and the symptoms—blurred ...

KAIST researchers have developed a groundbreaking drug that restores vision by inducing retinal nerve regeneration, marking the first long-term neural regeneration in mammalian retinas. This treatment ...

However, concerns regarding retinal detachment (RD) risk persist. Methods A systematic literature review and meta-analysis was performed in Medline and Scopus. The final search was updated on 30 March ...

Background There is no clinically relevant serological marker for the early detection of oesophageal adenocarcinoma (EAC) and its precursor lesion, Barrett’s oesophagus (BE). Objective To develop and ...

This hue, described as a highly saturated blue-green (similar to teal), was made visible using a novel technique called 'Oz,' which involves precise laser stimulation of specific retinal cells.

The FDA has granted Priority Review status to Regeneron’s and Bayer’s supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) injection 8 mg. The application seeks to expand use ...

"The ultimate goal is to provide programmable control over every photoreceptor [light-sensing cell] in the retina," primarily for research purposes, said co-first author James Fong, a doctoral ...

Retina Paints, operating in the Paints/Varnishes sector and classified as a Smallcap on the BSE, currently has its share price at ₹60.9. The stock has experienced fluctuations today, with a low ...

The sBLA seeks approval for Eylea HD to treat patients with macular edema following retinal vein occlusion (RVO), and for broadening the dosing schedule to include every 4-week (monthly) dosing across ...

The FDA's priority review of EYLEA HD targets macular edema post retinal vein occlusion and monthly dosing expansion. EYLEA HD's extended dosing intervals maintain efficacy, reducing treatment burden, ...